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ABSTRACT 20 
Functions of EBER RNAs were tested in lymphoblastoid cell lines containing EBER mutants of 21 
Epstein-Barr Virus (EBV). Binding of EBER1 to RPL22 was confirmed. Deletion of EBER1 or 22 
EBER2 correlated with increased cytoplasmic EBV LMP2 RNA and with small effects on 23 
specific cellular miRNA levels but protein levels of LMP1 and LMP2A were not affected. Wild 24 
type and EBER deletion EBV had approximately equal ability to infect immunodeficient mice 25 
reconstituted with a human haematopoietic system.  26 
  27 
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Epstein-Barr virus (EBV) encoded RNAs (EBERs) are abundant viral non-coding RNAs in EBV 28 
transformed lymphoblastoid cell lines (LCLs). We previously identified cell genes whose 29 
expression in EBV LCLs correlates with deletion of EBER1 or EBER2 (1); here we use LCLs to 30 
test various mechanisms that have been proposed for EBER function. 31 
Binding of EBER1 to RPL22 is confirmed in LCLs but no effect of EBER1 was detected on 32 
p53 protein level.  33 
EBER1 can bind to ribosomal protein L22 (RPL22) (2) and studies on RPL22 knockout mice (3, 34 
4) showed a p53 dependent defect in pro B cells (4). The effect is thought to involve RPL22 35 
binding to p53 mRNA, reducing translation of p53 (5).  Possibly EBER1 could modulate this 36 
pathway, although EBV infects mature B cells, in which no RPL22 phenotype was reported 37 
(4).  We confirmed binding of RPL22 to endogenous EBER1 in extracts of an LCL (Fig 1A).  38 
The p53 protein level was determined by western blotting in LCLs and the response to 39 
cisplatin treatment, which stabilizes p53, was also tested. There was no significant 40 
difference in the p53 levels or responses between the cells with or without EBER1 41 
expression (Fig 1B) so EBER1 does not appear to affect p53 expression in LCLs.  42 
Effect of EBERs on cellular miRNAs 43 
To determine whether the EBERs might affect cellular miRNAs, we used LCLs containing wild 44 
type (wt) B95-8 BAC EBV, EBER1 or EBER2 deletion mutants, or revertant viruses.  Total RNA 45 
was isolated from each LCL and small RNAs were used to generate Illumina sequencing 46 
libraries (6).  Appropriate expression of the EBER1 and EBER2 RNAs was confirmed by 47 
northern blotting (Fig 2A).  48 
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Sequencing detected miRNAs from all 8 EBV B95-8 pre-miRNAs and 491 mature human 49 
cellular miRNAs. Sequence reads are available at NCBI BioProject  PRJNA287267. The 50 
general pattern of viral and cellular miRNA expression was comparable to that observed 51 
previously in EBV B95-8 LCLs (6); miR-155, miR-146a/b, and miRNAs encoded within the 52 
miR-17/92 cluster were highly abundant and the EBV miRNAs constituted ~12% of the 53 
population (Table S1).  As in prior studies (6-8), we found no evidence for production of 54 
discrete miRNA-like products from the EBER RNAs.   55 
Sixteen miRNAs (p-value < 0.01 and -2 > logFC > 2) had expression levels altered in response 56 
to the deletion of EBER1, while eleven miRNAs were changed in response to EBER2 deletion 57 
(Table S2). There were significant differences in the levels of miR-340-3p, miR-340-5p, miR-58 
190a-3p, miR-190a-5p, and miR-33a-5p in EBER1-deleted LCLs compared to wt LCLs (Fig. 2B-59 
D, Table S2). Only small changes in miRNA expression levels (such as miR-199a) were 60 
observed in EBER2-deleted LCLs (Fig. 2D, Table S2).  Both the -3p and -5p miRNAs for miR-61 
190 and miR-340 were affected by the deletion of EBER1, indicating that the promoters 62 
driving expression of the primary miRNA transcripts are affected (Fig. 2B), consistent with a 63 
recent report on miR-190 (9).    64 
Additional Taqman quantitative RT-PCR assays on RNA from independently established LCLs 65 
supported expression of both miR-340-5p and -3p correlating with EBER1 expression (Fig 2E) 66 
but the fold change was lower in this assay. Since the levels of these miRNAs are all quite 67 
low in LCLs (Fig 2B, Table S1), we conclude that it is unlikely that the main function of EBERs 68 
in LCLs is to alter levels of cellular miRNAs but the changes in miRNA expression may 69 
contribute to the effects we reported previously on cellular mRNA levels in LCLs (1).    70 
 71 
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Deletion of EBER1 or EBER2 correlates with raised level of LMP2 RNAs in LCLs 72 
Recently EBER2 was shown to bind PAX5 and to promote PAX5 binding to the terminal 73 
repeat region of the EBV genome (10). Knockdown of EBER2 by siRNA caused a 50% increase 74 
in LMP1 and LMP2 RNA levels (10). Using qPCR with the same primers on cytoplasmic RNA, 75 
we did not observe any significant difference in the level of LMP1 RNA between the EBER2 76 
deletion LCLs or wild type EBV LCLs but LMP2A and LMP2B RNA levels were 2-3 fold higher 77 
when either EBER1 or EBER2 was deleted (Fig 3A,B), particularly when the cDNA synthesis 78 
was primed with oligo-dT (Fig 3B). LMP1 and LMP2A protein levels are quite variable in LCLs, 79 
shown in Fig 3C, and there was no apparent correlation with EBER expression. Our results 80 
thus provide some support for EBER2 tending to reduce the level of LMP2 RNA (10) but the 81 
specific binding of EBER2 to PAX5 and association with the terminal repeat may not mediate 82 
the LMP2 RNA effect we observed since there was an increase in LMP2 RNA when either 83 
EBER1 or EBER2 was deleted. The focus of the previous study on EBER2 meant that an effect 84 
of EBER1 deletion on LMP2 RNA levels was not tested in those experiments (10).  85 
Infection of mice with a human haematopoietic system with EBV lacking EBER genes 86 
Using the EBER mutant EBV strains, we tested whether EBERs affect establishment of EBV 87 
infection in NSG mice with a humanized haematopoietic system (11). In three separate 88 
experiments involving a total of 44 correctly reconstituted mice, there was no significant 89 
difference in the frequency of infection detected in the blood or the spleen with deletion of 90 
either or both EBER genes from the virus genome.  Spleen and blood viral loads are shown 91 
in Fig 4A.  92 
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Analyzing parameters of cell mediated immune responses towards the viral infections, we 93 
observed a tendency towards more pronounced CD8+ T cell expansion in the infection with 94 
EBER1 deficient viruses (Fig 4B). However, this tendency was primarily observed in one 95 
experiment and was not present in infections with an EBV virus deficient in both EBERs.  96 
Most studies have focussed on cell intrinsic functions for EBERs but they have also been 97 
reported to be released from cells (12) and in exosomes (13), potentially affecting immune 98 
or inflammatory responses (M Pegtel, personal communication). Most likely, physiological 99 
phenotypes for the EBERs will be revealed by in vivo infection challenged by normal immune 100 
responses. We have now shown that deletion of EBERs does not prevent infection of 101 
humanized mice, making this type of analysis possible.  102 
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FIGURE LEGENDS 167 
Figure 1 168 
A) Flag tagged RPL22 or negative control protein (C, Flag tagged Schlafen) were 169 
expressed by Neon transfection in an LCL containing B95-8 BAC EBV. Cell extracts 170 
were incubated with M2 anti-FLAG antibody (Sigma-Aldrich) bound to protein G 171 
sepharose beads.  RNA was extracted from the beads (IP) and the unbound 172 
supernatant (Sup) and tested for EBER RNA by northern blotting 173 
B) Three independent ΔEBER1 LCLs (light grey bars) or wt EBV LCLs (black bars) were 174 
treated with 20ug/ml cisplatin (C) in triplicate or untreated (U) as a control.  For each 175 
sample, 2ml of cell suspension (at 2.5 x 105 viable cells/ml, determined by trypan 176 
blue exclusion) was set up per well in 6 well plates, with or without cisplatin as 177 
indicated. The number of viable cells (excluding trypan blue) was quantified after 178 
16h and p53 protein was detected by western blotting of cell extracts made at the 179 
same time point. DO1 antibody (Santa Cruz) was used for detection of p53 by 180 
western blotting. Actin was used as loading control on the western blots.  181 
 182 
 183 
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Figure 2 184 
A) EBER1 and EBER2 expression in the wt and EBER-deleted LCLs used for deep 185 
sequencing analysis was confirmed by northern blotting (1).  0.5 ug of total RNA was 186 
used per well.  187 
B) Normalized miRNA reads counts for miR-190a and miR-340 in EBER1-deleted (delE1) 188 
LCLs compared to wild-type (wt) and EBER1 revertant (E1R) LCLs.  “A” and “B” 189 
denote the two individual LCLs analysed for each condition. About 10 million 190 
sequencing reads were obtained for each LCL library.  Reads were processed as 191 
described previously (6) using scripts from the fastx toolkit 192 
(http://hannonlab.cshl.edu/fastx_toolkit/).  To determine miRNAs, reads were 193 
aligned to the human (HG19) and EBV B95-8 genomes and annotated according to 194 
mirbase v21 (http://www.mirbase.org/). To determine miRNA expression levels, 195 
miRNA read counts were obtained using the quantifier module of miRDeep2 (14) 196 
(Table S1).  To identify differentially expressed (DE) miRNAs, miRNA read counts 197 
were analysed by edgeR using trimmed mean of M-values (TMM) for normalisation 198 
(15, 16).  A minimum of 40 reads per miRNA in at least one of the ten LCL libraries 199 
was required to be included in the analysis. DE miRNAs with a LogFC p value < 0.05 200 
are reported in Table S2. 201 
C) Normalized miRNA read counts for miR-33a in EBER1-deleted LCLs.  202 
D) Summary of fold changes (logFC) of select cellular miRNAs showing significant 203 
changes correlating with EBER1 or EBER2 expression as determined by deep 204 
sequencing and edgeR analysis.   205 
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E) Relative levels of miR-340-5p and miR-340-3p as determined by Taqman qRT-PCR 206 
assays in LCLs.  The expression levels of miRNAs were normalized to RNU48. The 207 
values represent means ± SE of 6 independent samples per EBV type (5 in the case of 208 
EBER1 revertants). The wild-type expression levels were set to 1 for each miRNA, 209 
whereas the levels of other samples were expressed relative to the wild type. Each 210 
cDNA sample was analysed in triplicate. 211 
 212 
Figure 3 213 
Cytoplasmic RNA from two LCLs each for EBV wild type (WT), deletion of EBER1 214 
(ΔE1), revertant (E1R), deletion of EBER2 (ΔE2) or revertant (E2R) was used for cDNA 215 
synthesis using either (A) random primers or (B) oligo dT using the ProtoScript First 216 
Strand cDNA Synthesis Kit (New England BioLabs).  Q-PCR with the same primers as 217 
in (10) was then used in duplicate assays to measure the levels of RNA for LMP1, 218 
LMP2A and LMP2B, using GAPDH as a reference. The 2-ΔΔCT method of comparative 219 
PCR (17) was used to analyse the results, expressed as fold change relative to the 220 
E1R LMP1 value.  (C) RIPA lysates were prepared from LCLs and equal amounts of cell 221 
protein were analysed by western immunoblotting. Membranes were probed with: 1/1000 222 
dilution of  anti-LMP2A  (Abcam, 14B7), 1/500 dilution of anti-LMP1 (DAKO, CS. 1-4), 1/5000 223 
dilution of anti-β actin (SIGMA, AC-74. Secondary antibodies were horseradish peroxidase-224 
conjugated sheep anti-mouse immunoglobulin (GE Healthcare) or horseradish peroxidase-225 
conjugated rabbit anti-Rat immunoglobulin (Sigma). Bound immunocomplexes were 226 
detected by enhanced chemiluminescence (GE Healthcare). 227 
 228 
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Figure 4 229 
A) Newborn HLA-A*0201 transgenic NOD/LtSz-Scid IL2RΔnull (NSG-A2tg) mice were 230 
irradiated and injected intrahepatically with CD34+ human hematopoietic progenitor 231 
cells as described previously (18). The reconstitution of human immune system 232 
components in the peripheral blood was analysed prior to the beginning of 233 
experiments (normally 12 weeks after engraftment). Groups of mice were infected 234 
with 105 infectious units of virus and monitored over a 4-8 week period in three 235 
experiments, each using different groups of reconstituted mice.  EBV viral loads were 236 
quantified in spleen and whole blood four weeks after infection for wild-type (EBV 237 
wt), EBER1 deficient (EΔ1), EBER2 deficient (EΔ2), EBER1 and 2 deficient (EΔ12) and 238 
EBER2 revertant (E2rev) viruses. 239 
B) CD8+ T cell expansion is slightly elevated in the absence of EBER1. CD8+ to CD4+ T cell 240 
ratio was assessed by flow cytometry after four weeks of infection with the same 241 
viruses as in A. The composition of blood and spleen samples from the humanized 242 
mice was analyzed using anti-human CD45 (HI30, Biolegend), anti-CD3 (UCHT1, 243 
Biolegend), anti-CD4 (RPA T4, Biolegend), anti-CD8 (SK1, Biolegend), anti-HLA-DR 244 
(L243, Biolegend), anti-CD45RO (UCHL1, BD Pharmingen) and anti-CD19 (HIB19, BD 245 
Pharmingen). Spleens were mechanically disrupted and filtered through a 70μm cell 246 
strainer. Erythrocytes were lysed in whole blood or in spleen suspensions using 247 
NH4Cl. Cell suspensions were stained with the indicated antibodies for 15min, 4°C 248 
and washed. Statistical analysis for all mouse experiments used two tailed T-tests. A 249 
P value of < 0.05 was considered statistically significant. 250 
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